TG Therapeutics, Inc. (NASDAQ:TGTX) to Post Q2 2024 Earnings of ($0.05) Per Share, B. Riley Forecasts

TG Therapeutics, Inc. (NASDAQ:TGTX) – Stock analysts at B. Riley upped their Q2 2024 earnings estimates for TG Therapeutics in a research report issued on Tuesday, April 30th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings of ($0.05) per share for the quarter, up from their prior forecast of ($0.06). B. Riley has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is ($0.10) per share. B. Riley also issued estimates for TG Therapeutics’ FY2024 earnings at ($0.14) EPS and FY2025 earnings at $0.78 EPS.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The business had revenue of $63.47 million for the quarter, compared to analyst estimates of $54.60 million. TG Therapeutics had a net margin of 14.24% and a return on equity of 33.79%. The company’s revenue for the quarter was up 713.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.28) earnings per share.

A number of other brokerages also recently weighed in on TGTX. LADENBURG THALM/SH SH upped their price objective on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. StockNews.com downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $25.00 price objective on shares of TG Therapeutics in a research report on Thursday, April 18th. The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday, February 29th. Finally, HC Wainwright upped their price objective on shares of TG Therapeutics from $45.00 to $49.00 and gave the stock a “buy” rating in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $29.83.

TG Therapeutics Trading Down 1.4 %

NASDAQ TGTX opened at $16.19 on Thursday. The company has a fifty day moving average of $15.19 and a 200 day moving average of $14.34. The company has a market capitalization of $2.50 billion, a PE ratio of 71.30 and a beta of 2.33. TG Therapeutics has a 1 year low of $6.46 and a 1 year high of $35.67. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18.

Institutional Trading of TG Therapeutics

Large investors have recently bought and sold shares of the business. Pingora Partners LLC purchased a new stake in TG Therapeutics during the 4th quarter valued at about $27,000. PNC Financial Services Group Inc. grew its stake in TG Therapeutics by 131.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,014 shares in the last quarter. Anchor Investment Management LLC purchased a new stake in TG Therapeutics during the 4th quarter valued at about $80,000. NBC Securities Inc. purchased a new stake in TG Therapeutics during the 3rd quarter valued at about $58,000. Finally, REDW Wealth LLC purchased a new stake in shares of TG Therapeutics in the 3rd quarter valued at approximately $84,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Insider Transactions at TG Therapeutics

In other news, Director Laurence N. Charney sold 22,000 shares of the business’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the completion of the sale, the director now owns 215,229 shares of the company’s stock, valued at $3,437,207.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 9.20% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.